NEW YORK (GenomeWeb) – Centogene announced today that it has signed an agreement to help Aldeyra Therapeutics identify patients with Sjögren-Larsson Syndrome (SLS) in support of its effort to develop a treatment for the rare genetic disease.

SLS is caused by mutations that adversely affect lipid metabolism, leading to scaly skin, intellectual disability, and spasticity. While there is no approved treatment for the inherited disorder, Aldeyra currently has a drug candidate — reproxalap — under phase II development.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.